ArticleToxins2022
The Serum Level of IL-31 in Patients with Chronic Kidney Disease-Associated Pruritus: What Can We Expect?
Article in Toxins, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 24 citations in OpenAlex.
- Chronic kidney disease-associated pruritus: a perspective on skin barrier damage.Renal failure · 2026Review
- Differences in Itch Quality Between Interleukin-31 and Thymus and Activation-Regulated Chemokine of Japanese Atopic Dermatitis.Mayo Clinic proceedings. Innovations, quality & outcomes · 2026Article
- Acquired reactive perforating collagenosis treated with nemolizumab.JAAD case reports · 2026Article
- Uremic Pruritus in Hemodialysis: Mechanisms, Burden, and Emerging Therapies.Journal of clinical medicine · 2026Review
- Effectiveness and renal safety of dupilumab in the treatment of moderate-to-severe atopic dermatitis patients with chronic kidney disease stages 4-5: a real-world cohort study in China.Frontiers in medicine · 2026Article
- Gut microbiota and the kidney-gut-skin axis in chronic kidney disease-associated pruritus: mechanisms and therapeutic implications.Frontiers in cellular and infection microbiology · 2026Review
- Role of Mast Cells and Their Mediators in Chronic Kidney Diseases.International journal of molecular sciences · 2025Review
- Real-World Evidence Demonstrating Nemolizumab's Rapid Efficacy in Recalcitrant Uremic Pruritus.Cureus · 2025Article
- Patient-Reported Outcome Measures in CKD-Associated Pruritus: A Systematic Review.Kidney medicine · 2025Review
- Effectiveness of Nemolizumab in Improving Dialysis-Associated Pruritus Refractory to Difelikefalin: A Case Report.Cureus · 2025Article
- Dupilumab relieves pruritus both in uremic pruritus and in atopic dermatitis with chronic kidney disease: a retrospective real-world study.Frontiers in medicine · 2025Article
- Data independent acquisition reveals in-depth serum proteome changes in uremic pruritus.Frontiers in physiology · 2024Article
- Treatment of renal pruritus with dupilumab monotherapy: A case report.SAGE open medical case reports · 2024Article
- Neurotrophin-4 and Brain-Derived Neurotrophic Factor Serum Levels in Renal Transplant Recipients with Chronic Pruritus.Dermatology and therapy · 2023Article
- Interaction of S100A6 Protein with the Four-Helical Cytokines.Biomolecules · 2023Article
- Blockage of the IL-31 Pathway as a Potential Target Therapy for Atopic Dermatitis.Pharmaceutics · 2023Review
- High Serum IL-31 Concentration Is Associated with Itch among Renal Transplant Recipients.Journal of clinical medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic-kidney-disease-associated pruritus (CKD-aP) is one of the most common and burdensome dermatological symptoms affecting patients undergoing dialysis, and its etiopathogenesis has still not been fully discovered. This study was designed to investigate the possible contribution of interleukin-31 (IL-31) to the pathogenesis of itch in patients undergoing maintenance hemodialysis (HD). We evaluated the serum level of IL-31 in HD patients with pruritus, in HD patients without pruritus and in healthy controls, as well as its correlation to the severity of itch. The study enrolled 175 adult subjects. The participants were divided into three groups. Group A included 64 patients on maintenance HD with CKD-aP, Group B included 62 patients on maintenance HD not reporting CKD-aP and Group C included 49 healthy controls. Pruritus severity was assessed using the Numerical Rating Scale (NRS), and the serum levels of IL-31 were measured. The results showed that the IL-31 serum level was significantly higher in the itchy group (p < 0.001) in comparison to the patients free from pruritus. Moreover, a marginal trend towards significance (r = 0.242, p = 0.058) was observed between the IL-31 serum level and itch intensity. Our study supports earlier findings on the extended role of IL-31 in the development of CKD-aP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.